The company that invented the Band-Aid separated from it. In 2023, Johnson & Johnson spun off its consumer health division as Kenvue and remade itself into a pure innovation company: Innovative Medicine and MedTech. In 2025 it posted $94.2 billion in revenue, employed 138,200 people, and held 28 products each generating more than $1 billion annually. It is the only OPPI member operating at scale in both pharmaceuticals and medical devices.
There is a number that separates Johnson & Johnson from every other healthcare company on Earth: twenty-eight. That is the count of individual products and platforms, each generating more than one billion dollars in annual sales. Not twenty-eight therapeutic areas. Not twenty-eight business units. Twenty-eight discrete products, each large enough to be a standalone company.
In oncology alone, Darzalex treats multiple myeloma with a mechanism,anti-CD38 monoclonal antibody,that has redefined first-line therapy. Erleada targets metastatic prostate cancer. Imbruvica, a BTK inhibitor, has become a standard of care across multiple blood cancers. These are not portfolio fillers. They are franchise anchors, and Johnson & Johnson had 51 innovative medicine regulatory approvals in 2025.
In immunology, Stelara built one of the largest biologic franchises in the industry before its patent expiration, and Tremfya has stepped into the succession with a differentiated mechanism in psoriasis and psoriatic arthritis. In neuroscience, Spravato,esketamine for treatment-resistant depression,opened a category that most pharmaceutical companies avoided because the regulatory and clinical pathway was considered too difficult. In cardiovascular medicine, Xarelto became one of the most widely prescribed anticoagulants globally. The breadth is not accidental. It is the result of a company that has, for decades, run its pharmaceutical pipeline like a diversified investment portfolio: deliberate bets across multiple therapeutic areas, with the understanding that concentration risk in any single disease is existential.
For 138 years, Johnson & Johnson was three things at once: a pharmaceutical company, a medical device company, and a consumer goods company. Band-Aid, Tylenol, Listerine, Neutrogena,these were not side businesses. They were the brands that made J&J a household name, the products that gave the company an emotional presence in homes that no drug manufacturer could otherwise achieve. And in 2023, J&J separated from all of them.
The consumer health division was spun off as Kenvue in what became the most significant corporate restructuring in Johnson & Johnson’s history. The logic was clinical. Consumer health is a marketing-intensive, margin-stable, low-growth business. Innovative medicine and medical technology are R&D-intensive, margin-volatile, high-growth businesses. Bundling them together forced a single management team to optimise for contradictory objectives. The separation allowed each entity to allocate capital according to its own growth logic.
What remained was a Johnson & Johnson built entirely around innovation: the Innovative Medicine segment, generating over $55 billion in revenue, and MedTech, generating over $32 billion. The company that emerged from the Kenvue separation is unrecognisable from the one that preceded it. It is leaner, more focused, and more dependent on R&D productivity than at any point in its history. In 2025, its first full year of operation as a pure innovation company, Johnson & Johnson posted $94.2 billion in revenue with 5.3% operational growth and secured over 40 MedTech regulatory approvals alongside those 51 innovative medicine approvals.
Johnson & Johnson holds the fourth-highest India patent portfolio among all OPPI members: 1,512 filings at the Indian Patent Office between 1996 and 2026, with 139 granted. The number does not appear under a single name. Much of J&J’s pharmaceutical innovation files through Janssen, the subsidiary that serves as the company’s primary research and development engine.
The Janssen connection matters because it reveals how J&J’s innovation actually works. Johnson & Johnson acquired the Belgian pharmaceutical company Janssen Pharmaceutica in 1961, and rather than absorbing it into a centralised R&D structure, kept it as a distinct research organisation with its own scientific culture, leadership, and therapeutic focus areas. Darzalex, Stelara, Tremfya, Imbruvica, Erleada, Carvykti,these molecules trace their origins to Janssen laboratories. When you see a patent filing in India from “Janssen,” you are looking at the same innovation engine that produced Johnson & Johnson’s pharmaceutical franchise.
The 139 grants from 1,512 filings reflect the reality of Indian patent law, where Section 3(d) imposes a higher bar for pharmaceutical patents than most jurisdictions. A 9.2% grant rate is not a failure rate. It is the cost of doing business in a patent system that was explicitly designed to scrutinise incremental innovation claims. What matters is that J&J continues to file. The portfolio is active, current, and growing,a sign that the company treats India as a market worth protecting with intellectual property, not merely a distribution territory.
Most large healthcare companies choose a lane. Roche is pharmaceuticals and diagnostics. Medtronic is devices. Pfizer is drugs. Johnson & Johnson refused to choose, and the result is a company that operates two businesses, each of which would independently rank among the largest healthcare companies in the world.
Innovative Medicine, generating over $55 billion in revenue, is the pharmaceutical arm. It houses the oncology, immunology, neuroscience, cardiovascular, and pulmonary hypertension franchises. This is where Darzalex lives, where Carvykti,J&J’s CAR-T cell therapy for relapsed or refractory multiple myeloma,represents one of the most advanced manufacturing challenges in modern medicine: harvesting a patient’s own T cells, genetically engineering them to target cancer, and reinfusing them. Each dose is a bespoke product manufactured for a single patient.
MedTech, generating over $32 billion in revenue, is the other machine. Surgical robots that assist orthopaedic procedures. Joint replacement implants engineered to last decades inside the human body. Contact lenses worn by millions daily. Wound closure devices used in operating theatres worldwide. The MedTech segment secured over 40 regulatory approvals in 2025 alone.
The strategic advantage of running both machines is not diversification for its own sake. It is the intersection. When J&J develops an oncology drug and also manufactures the surgical instruments used to treat the same cancer, it operates across the full continuum of patient care. When it innovates in orthopaedic implants and also develops the pharmaceutical therapies that manage post-surgical recovery, it has a clinical perspective that pure-play competitors cannot replicate. In 2024, the combined enterprise generated $88.8 billion in revenue with 138,100 employees and 7% operational growth. By 2025, that had grown to $94.2 billion with 138,200 employees.
Sources: Johnson & Johnson Annual Reports 2024–2025. Johnson & Johnson Proxy Statement 2026. Indian Patent Office (patent filing data). OPPI member directory.